Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

May 24, 2024

[Molecular Cancer Therapeutics] The PKMYT1 inhibitor lunresertib with gemcitabine selectively and synergistically reduced the viability of endocrine therapies and palbociclib-resistant ER+ breast cancer cells without functional p53.

ELF3 Plays an Important Role in Defining TRAIL Sensitivity in Breast Cancer by Modulating the Expression of Decoy Receptor 2 (DCR2)

May 24, 2024

[Molecular Biology Reports] ELF3 overexpression in breast cancer cells caused reversal of TRAIL resistance as observed using cell viability assay and cleaved caspase-3 immunoblotting.

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

May 22, 2024

[Clinical Cancer Research] Expression of G1/S-phase cell cycle regulators were evaluated alongside EGFR in breast cancer. The authors conjugated cetuximab with CDK inhibitor SNS-032, for specific delivery to EGFR-expressing cells and assessed antibody drug conjugate internalization, and its anti-tumor functions in vitro and in orthotopically-grown basal-like/TNBC xenografts.

Emerging Treatments in HER2-Positive Advanced Breast Cancer: Keep Raising the Bar

May 22, 2024

[Cell Reports Medicine] The authors review the evolving treatment landscape of HER2-positive breast cancer, from the current approved therapies to the future perspectives, with a focus on the new agents which are likely to get approved in the next future.

Edgewood Oncology Announces First Patients Dosed in Phase IIa Study of BTX-A51 in Genetically-Defined Breast Cancer

May 22, 2024

[Edgewood Oncology] Edgewood Oncology announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha and cyclin-dependent kinases 7 and 9, that synergistically targets master regulators of cancer.

FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

May 22, 2024

[Genentech, Inc.] Genentech announced that the US FDA has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.

Spatially Distinct Epithelial and Mesenchymal Cell Subsets Along Progressive Lineage Restriction in the Branching Embryonic Mammary Gland

May 21, 2024

[EMBO Journal] Using single-cell RNA sequencing, researchers produced an atlas of matched mouse mammary epithelium and mesenchyme and reconstructed the differentiation trajectories of multipotent stem cells toward basal and luminal fate.

A Functional Survey of the Regulatory Landscape of Estrogen-Receptor-Positive Breast Cancer Evolution

May 21, 2024

[Cancer Discovery] Scientists employed functional genomics to dissect the contribution of cis-regulatory elements (CREs) to cancer evolution. Parallel epigenetic perturbation in vitro revealed context-dependent roles for many CREs, with a specific impact on dormancy entrance and endocrine therapy resistance.

Plant-Derived Anti-Human Epidermal Growth Factor Receptor 2 Antibody Suppresses Trastuzumab-Resistant Breast Cancer With Enhanced Nanoscale Binding

May 21, 2024

[ACS Nano] A variety of biophysical techniques, in vitro assays, and in vivo experiments uncovered the plant-derived anti-human epidermal growth factor receptor 2 (HER2) antibody's nanoscale binding dynamics with transmembrane HER2 on living cells.

Epigenetic Activation of SOX11 is Associated with Recurrence and Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer

May 21, 2024

[British Journal Of Cancer] Human cell lines and mouse models of disease progression were analyzed for candidate risk predictive biomarkers identified and validated in two independent ductal carcinoma in situcohorts.

Sympathetic Nerve Signals: Orchestrators of Mammary Development and Stem Cell Vitality

May 16, 2024

[Journal Of Molecular Cell Biology] Using a mouse mammary gland model, investigators delved into the regulatory role of sympathetic nervous signaling in the context of mammary stem cells and mammary development.

Resf1 Is a Compound G4 Quadruplex-Associated Tumor Suppressor for Triple Negative Breast Cancer

May 16, 2024

[PLOS Genetics] Researchers identified Resf1 as a novel metastasis susceptibility gene in ER- breast cancer. Reduction of Resf1 resulted in a significant increase in tumor growth, a shortened overall survival time, and increased incidence and number of lung metastases, consistent with patient data.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.